GGrantIndex
← Leaderboards

Elizabeth Clarice Verna

Columbia University Health Sciences

$4,269,042
Attributed
$6,582,951
Total exposure
5
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY201525
$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,582,951 · 5

By mechanism

U01$4,180,235 · 2
R01$1,314,963 · 1
K23$640,169 · 1
R21$447,584 · 1

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Cirrhosis

Research focus

CirrhosisProspectiveLiver DiseasesLiver CirrhosisPreventLiver TransplantationBiological MarkersPharmaceutical PreparationsMortalityPreventionInflammationHepaticClinical TrialsSerumTranslational ResearchLifePathway InteractionsCessation Of LifePlayDisease ProgressionMicrobiomeFutureCohortInsight

Grant awards (19)

Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma$656,499
U01 · FY2025 · CA
2/4-The INTEGRATE Study: Evaluating INTEGRATEd care to Improve Biopschosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease$434,374
R01 · FY2025 · AA · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$417,897
U01 · FY2025 · DK
2/4-The INTEGRATE Study: Evaluating INTEGRATEd care to Improve Biopschosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease$434,338
R01 · FY2024 · AA · contact PI
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$419,793
U01 · FY2024 · DK
Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma$311,876
U01 · FY2024 · CA
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$292,750
U01 · FY2024 · DK
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$622,831
U01 · FY2023 · DK
2/4-The INTEGRATE Study: Evaluating INTEGRATEd care to Improve Biopschosocial Outcomes of Early Liver Transplantation for Alcohol-Associated Liver Disease$446,251
R01 · FY2023 · AA · contact PI
Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma$341,920
U01 · FY2023 · CA
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$574,395
U01 · FY2022 · DK
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$189,021
U01 · FY2022 · DK
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis Network$353,253
U01 · FY2021 · DK
Gut Microbiota in the Modulation of Outcomes after Liver Transplant$236,219
R21 · FY2021 · TR
Gut Microbiota in the Modulation of Outcomes after Liver Transplant$211,365
R21 · FY2020 · TR
Bacterial Translocation and the Intestinal Microbiome in Recurrent Disease Following Liver Transplantation$167,724
K23 · FY2018 · DK · contact PI
Bacterial Translocation and the Intestinal Microbiome in Recurrent Disease Following Liver Transplantation$167,724
K23 · FY2017 · DK · contact PI
Bacterial Translocation and the Intestinal Microbiome in Recurrent Disease Following Liver Transplantation$151,610
K23 · FY2016 · DK · contact PI
Bacterial Translocation and the Intestinal Microbiome in Recurrent Disease Following Liver Transplantation$153,111
K23 · FY2015 · DK · contact PI